Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
About Lexicon Pharmaceuticals, Inc.Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. We use proprietary gene knockout technology to systematically discover the physiological functions of genes in mice and to identify which corresponding human genes encode potential targets for therapeutic intervention, or drug targets. For those targets that we consider to have high pharmaceutical value, we engage in programs for the discovery and development of potential small molecule drugs, therapeutic antibodies and therapeutic proteins. Our physiology-based approach to understanding gene function and our use of mouse models in our drug discovery efforts allow us to make highly-informed decisions throughout the drug discovery and development process, which we believe will increase our likelihood of success in discovering breakthrough therapeutics.
We use solution-phase chemistry to generate diverse libraries of optically pure compounds that are targeted against the same pharmaceutically relevant gene families that we address in our Genome5000 program. These libraries are built using highly robust and scalable organic reactions that allow us to generate compound collections of great diversity and to specially tailor the compound collections to address various therapeutic target families. We design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds. We can rapidly reassemble these building blocks to generate optimization libraries when we identify a hit against one of our in vivo-validated targets, enabling us to rapidly optimize those hits and accelerate our medicinal chemistry efforts.
Our medicinal chemistry technology is housed in a state-of-the-art 76,000 square foot facility in Hopewell, New Jersey. Our lead optimization chemistry groups are organized around specific discovery targets and work closely with their pharmaceutical biology counterparts in our facilities in The Woodlands, Texas. The medicinal chemists optimize lead compounds in order to select clinical candidates with the desired absorption, distribution, metabolism, excretion and physicochemical characteristics. We have the capability to profile our compounds using the same battery of in vivo assays that we use to characterize our drug discovery targets. This provides us with valuable detailed information relevant to the selection of the highest quality compounds for clinical development.
Last Updated: 03-16-04
343 articles with Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical UpdateConference Call and Webcast at 8:00 am Eastern Time
Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended September 30, 2020 and provided an update of key milestones.
Lexicon Pharmaceuticals to Host Third Quarter 2020 Financial Results Conference Call and Webcast on October 29, 2020
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2020 financial results on Thursday, October 29, 2020 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a clinical update.
Lexicon Pharmaceuticals, Inc. announced the completion of the sale of Lexicon’s rights, title and interest in XERMELO® to TerSera Therapeutics LLC.
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1). “We are pleased to progress with patient dosing in our first proof-of-
Lexicon Pharmaceuticals to Participate in the Citi 15ᵗʰ Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference
Jeffrey L. Wade, Lexicon’s executive vice president, corporate and administrative affairs and chief financial officer, will make a live webcast company presentation for the Wells Fargo conference on Thursday, September 10, 2020 at 2:00 p.m. ET.
GTCR, a leading private equity firm, announced that its TerSera Therapeutics LLC portfolio company has entered into a definitive agreement to acquire the product Xermelo® from Lexicon Pharmaceuticals, Inc. for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update21% Increase in XERMELO® U.S. Net Sales
Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended June 30, 2020.
Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELOLexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer
Lexicon Pharmaceuticals, Inc. and TerSera Therapeutics LLC announced that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, title and interest in XERMELO®.
Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020
Lexicon Pharmaceuticals, Inc., will release its second quarter 2020 financial results on Thursday, July 30, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m.
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes
Lexicon Pharmaceuticals, Inc., announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS.
Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference
Lexicon Pharmaceuticals, Inc., announced that four posters highlighting XERMELO® will be presented at the virtual Cholangiocarcinoma Foundation Annual Conference.
Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for Zynquista TM (sotagliflozin) at the virtual 80 th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safety data patients with type 2 diabetes and moderate and severe renal impairment. Phase 3 CKD-3 Study In the Phase 3, multicenter, randomized, double-blind, placebo-controlled CKD-3 study, sotagliflozin was tes
Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020)
Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended March 31, 2020.
Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020
Lexicon Pharmaceuticals, Inc. will release its first quarter 2020 financial results on Monday, April 27, 2020 before market opens.
Lexicon Pharmaceuticals, Inc. will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants..
LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAMLong-Term Outcomes Studies, SCORED and SOLOIST, to Close Out Early
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today provided an update on its ZynquistaTM (sotagliflozin) program in type 2 diabetes, heart failure and chronic kidney disease. The company will close out early the two long-term outcomes studies of sotagliflozin, SCORED and SOLOIST, designed to demonstrate benefits in and support labeling for heart failure and chronic kidney disease.
LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neuroendocrine Tumor Society (ENETS) meeting (March 11-13)